Intellia Therapeutics, Inc.
NTLAIntellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
NTLA-2002
Hereditary Angioedema
NTLA-2001
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
nexiguran ziclumeran
Neuromuscular Disease
Biological NTLA-2002
Hereditary Angioedema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NTLA-2002 | Phase 3 | Hereditary Angioedema | - | - |
NTLA-2001 | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | - | - |
nexiguran ziclumeran | Phase 3 | Neuromuscular Disease | - | - |
Biological NTLA-2002 | Phase 2 | Hereditary Angioedema | - | - |